Determination of meloxicam in human plasma administrated with four drugs by LC method: application to a pilot bioavailability study by Leal, Leila B. et al.
1883ISSN 0326-2383
KEY WORDS: Meloxicam, Bioanalytical method, pharmacokinetic study, Reversed-phase liquid chromatography.
* Author to whom correspondence should be addressed. E-mail: leila.leal@nudfac.com.br
Latin American Journal of Pharmacy
(formerly Acta Farmacéutica Bonaerense)
Lat. Am. J. Pharm. 30 (10): 1883-8 (2011)
Regular Article
Received: August 18, 2011
Revised version: October 24, 2011 
Accepted: October 25, 2011
Determination of Meloxicam in Human Plasma Administrated with
Four Drugs by LC Method: Application to a Pilot Bioavailability Study
Leila B. LEAL 1*, Danilo C.G. BEDOR 1, Elayne K.S. MELO 1,
Eduardo J. OLIVEIRA 2 & Davi P. SANTANA 1
1 Núcleo de Desenvolvimento Farmacêutico e Cosmético – Universidade Federal de Pernambuco,
Rua Professor Arthur de Sá s/n, Cidade Universitária, CEP 50740-520, Recife, Pernambuco, Brasil.
2 Laboratório de Tecnologia Farmacêutica, Universidade Federal da Paraíba (LTF-UFPB), Brasil.
SUMMARY. The development and validation of a simple and accurate method by HPLC-UV to quantify
meloxicam (MLX) in human plasma and its application to comparative bioavailability study between
MLX formulation and manipulated meloxicam + prednisone + cyclobenzaprine + diacerein + hidroxy-
chloroquine is described. MLX and the internal standard (piroxicam) were extracted from plasma using
protein precipitation. Chromatographic separation of meloxicam, piroxicam, other active ingredients, di-
acerein metabolite (Rhein) and plasma interferents was achieved with a C18 column, using a mobile phase
of 20 mM sodium Hydrogen pH 3.0 and acetonitrile, with detection at 360 nm and retention times of 4.7,
3.7 and 4.1 min, respectively.  The method was linear over the concentration range of 50 to 3000 ng/mL,
meloxicam and piroxicam had an average recovery from plasma of 96 and 97 %, respectively. The preci-
sion and accuracy (intra-, inter-day) were less than 6 %. The method was successfully applied to a pilot
pharmacokinetic study.
